Cargando…

Correction to: The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma

Detalles Bibliográficos
Autores principales:	Shui, Lin, Li, Xiaofen, Peng, Yang, Tian, Jiangfang, Li, Shuangshuang, He, Du, Li, Ang, Tian, Bole, Li, Mao, Gao, Heli, An, Ning, Yi, Cheng, Cao, Dan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361738/ https://www.ncbi.nlm.nih.gov/pubmed/34384437 http://dx.doi.org/10.1186/s12967-021-02997-x

Ejemplares similares

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2021)

Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review)
por: Huang, Xing, et al.
Publicado: (2021)

Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis
por: Thibodeau, My Linh, et al.
Publicado: (2019)

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Early recurrence detected by (18)F-FDG PET/CT in patients with resected pancreatic ductal adenocarcinoma
por: Wang, Li, et al.
Publicado: (2020)

Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma
por: Ryu, Kum Hei, et al.
Publicado: (2023)

Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next‐generation sequencing
por: Jiang, Huiqin, et al.
Publicado: (2023)

DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives
por: Stoof, Jojanneke, et al.
Publicado: (2021)

Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma
por: Wu, Hongjin, et al.
Publicado: (2021)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma
por: Li, Tianjiao, et al.
Publicado: (2019)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma
por: Li, Junjie, et al.
Publicado: (2016)

Germline Variants in DNA Damage Repair Genes: An Emerging Role in the Era of Precision Medicine in Pancreatic Adenocarcinoma
por: Shoucair, Sami, et al.
Publicado: (2021)

Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma
por: Cao, Ying-Ying, et al.
Publicado: (2023)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Metabolism remodeling in pancreatic ductal adenocarcinoma
por: Li, Jin-Tao, et al.
Publicado: (2019)

Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma
por: Huang, Yan, et al.
Publicado: (2014)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
por: Tong, Yexin, et al.
Publicado: (2022)

Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma
por: Koh, Youngil, et al.
Publicado: (2023)

Diagnostic rate of germline pathogenic variants in pancreatic ductal adenocarcinoma patients using whole genome sequencing
por: Chung, An-Ko, et al.
Publicado: (2023)

Immunotherapy for deficient mismatch repair (dMMR) pancreatic ductal adenocarcinoma
por: Ebia, Matthew I., et al.
Publicado: (2023)

Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021)

MRGBP as a potential biomarker for the malignancy of pancreatic ductal adenocarcinoma
por: Ding, Feng, et al.
Publicado: (2017)

Mimics of pancreatic ductal adenocarcinoma
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Pancreatic ductal adenocarcinoma staging
por: Al-Hawary, Mahmoud M., et al.
Publicado: (2013)

Syndecans and Pancreatic Ductal Adenocarcinoma
por: Betriu, Nausika, et al.
Publicado: (2021)

Models of pancreatic ductal adenocarcinoma
por: Dennaoui, Rayane, et al.
Publicado: (2021)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

Acute pancreatitis in patients with pancreatic cancer: Timing of surgery and survival duration
por: Li, Shaojun, et al.
Publicado: (2017)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective
por: Zhang, Wu-Hu, et al.
Publicado: (2020)

Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
por: Meng, Fan, et al.
Publicado: (2021)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

Pancreatic Ductal Adenocarcinoma Associated with Autoimmune Pancreatitis
por: Pezzilli, Raffaele, et al.
Publicado: (2011)

Claudin 18.2 is a potential therapeutic target for zolbetuximab in pancreatic ductal adenocarcinoma
por: Wang, Xi, et al.
Publicado: (2022)

Pancreatic and duodenal homeobox-1 in pancreatic ductal adenocarcinoma and diabetes mellitus
por: Tang, Zhen-Chu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g2oa2uldq42poq7o6595o1so3q